Drug prices are unjustifiably high and pharmaceutical companies too often conduct “uninformative” trials that fail to use appropriate comparators, according to an HTA official from Norway.
Companies will face increasingly punitive measures to control drug prices if nothing changes, including tendering for novel products and increased price transparency, the official warned.
Companies have a social responsibility to deliver innovative products at reasonable prices that protect the sustainability of health care systems in Europe.

HTA Expert Warns Of Escalating Measures If Pharma Fails To Tame Prices

More from Market Access